Jiangsu Hengrui Pharmaceutical: Hengrui Acquires PI3k Inhibitor Rights from Shanghai Lingli Pharma

Jiangsu Hengrui Medicine acquired China rights to a PI3kδ inhibitor (YY-20394) from Shanghai Yingli Pharma. Hengrui will make a $20 million investment in Yingli, and it will be responsible for clinical development of the candidate. PI3kδ inhibitors are expected to be effective treatments for hemotological tumors. Founded in 2011, Yingli Pharma is a small-molecule novel drug R&D company focused on treatments for hematological tumors, solid tumors and kidney-related metabolic diseases. It has an R&D center in Zhangjiang Park. More details....Stock Symbol: (SHA: 600276)Share this with colleagues: